Annemasse

This research aims to evaluate muscle strength improvements in men with prostate cancer undergoing androgen deprivation therapy. The study compares a muscle strengthening program with and without the addition of neuromuscular electrostimulation. It is a prospective, longitudinal, randomized study conducted at a single center, following recommended care for prostate cancer patients on hormonal treatment. Participants will take part in 77 activity sessions involving muscle strengthening, testing, or unloading exercises as part of a nutritional and sports support program. The study groups will differ by whether they receive neuromuscular electrostimulation alongside the physical activity program. Treatment and monitoring will occur over a period extending to at least six months. During the study, researchers will measure the maximum load resistance lifted by the quadriceps muscle after six months to assess muscle strength. Participants will be monitored regularly, with evaluations focused on physical performance and safety related to the interventions. The study aims to better understand how adding electrostimulation may affect muscle strength in this patient group.

Colorectal cancer mainly affects elderly patients, with over half of new cases in France occurring in those aged 70 or older. Adjuvant chemotherapy has shown benefits in disease-free and overall survival after stage III colon cancer surgery, but its use in elderly patients remains limited. This phase III randomized study explores whether adjuvant chemotherapy improves disease-free survival in elderly patients and which chemotherapy regimen is most effective, addressing concerns about benefits for both unfit and fit elderly patients. Participants will be divided into two groups based on a multidisciplinary evaluation including a geriatrician. One group will receive fluoropyrimidine-based chemotherapy (LV5FU2 or capecitabine), and the other will receive oxaliplatin-based chemotherapy (FOLFOX4 or XELOX). Some patients may be assigned to observation only. Treatments will begin within 12 weeks after surgery. The study also evaluates specific biological markers common in elderly tumors, such as mismatch repair deficiency. During the study, participants will undergo assessments including geriatric questionnaires and medical monitoring. Researchers will track disease-free survival over three years following the last patient's enrollment. Safety and treatment effects will be monitored, with exclusion of patients expected to live less than four years or those unable to comply with follow-up. The study aims to better understand chemotherapy benefits in an elderly population after colon cancer surgery.